Overview


According to FutureWise analysis the market for colony stimulating factors in 2023 is US$ 8.59 billion, and is expected to reach US$ 19.68 billion by 2031 at a CAGR of 10.90%.

Colony stimulating factors are glycoproteins that promote the formation of white blood cells in response to infection (mostly granulocytes such as neutrophils). Exogenous colony stimulating chemicals stimulate bone marrow stem cells to produce more specific type of white blood cell. The new white blood cells enter the bloodstream and immediately start battling the infection. Colony stimulating drugs are given to cancer patients who have low white blood cell counts (neutropenia) and are at risk of infection as a result of their treatment. Colony stimulating medications help patients spend less time neutropenic. Colony stimulating factors (CSFs) are produced by a number of cells in our bodies and have the ability to travel throughout the body, connecting to cells with particular CSF receptors. Because CSFs can increase the production of immune cells, they are utilised as medicines to boost the creation of white blood cells. This could be a life-saving treatment for patients whose immune systems have been destroyed by chemotherapy or certain immunodeficiency disorders. CSFs are also important medications for the transplantation of blood stem cells. The increased prevalence of cancer is expected to have an impact on the market for colony stimulating factors. Another element driving market expansion is the rising need for prophylaxis granulocyte colony-stimulating factor (G-CSF). G-CSF prophylaxis lowers the risk of febrile neutropenia (FN), allowing patients to stay on their myelosuppressive medications.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Colony Stimulating Factors Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Colony Stimulating Factors Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Intas Pharmaceuticals Ltd.
  • Sanofi
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Biocon
  • Dr. Reddy’s Laboratories Ltd.
  • Amgen Inc.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Stada Arzneimittel AG
  • Emcure Pharmaceuticals Limited.
  • Celltrion, Inc
  • Biocad
  • Coherus BioSciences
  • Johnson and Johnson Private Limited
  • Eli Lilly and Company.
  • Abbott

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Macrophage–Colony-Stimulating Factor (M-CSF)
  • Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3)
  • Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)
  • Granulocyte–Colony-Stimulating Factor (G-CSF)

By Drug

  • Pegfilgrastim
  • Tbo-filgrastim
  • Sargramostim
  • Filgrastim

By Application

  • Aplastic Anemia
  • Bone Marrow Transplantation
  • Neutropenia
  • Neutropenia Associated with Chemotherapy
  • Neutropenia Associated with Radiation
  • Peripheral Progenitor Cell Transplantation

By Dosage

  • Injection
  • Tablets
  • Capsule
  • Others

By Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Colony Stimulating Factors Market By Type, By Drug, By Application, By Dosage, By Route of Administration, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping-product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Colony Stimulating Factors Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Colony Stimulating Factors Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Colony Stimulating Factors Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Colony Stimulating Factors Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Macrophage–Colony-Stimulating Factor (M-CSF)
        2. Multiple-Colony-Stimulating Factor or Interleukin 3 (IL-3)
        3. Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)
        4. Granulocyte–Colony-Stimulating Factor (G-CSF)

  • 8.   Colony Stimulating Factors Market, By Drug Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pegfilgrastim
        2. Tbo-filgrastim
        3. Sargramostim
        4. Filgrastim

  • 9.   Colony Stimulating Factors Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Aplastic Anemia
        2. Bone Marrow Transplantation
        3. Neutropenia
        4. Neutropenia Associated with Chemotherapy
        5. Neutropenia Associated with Radiation
        6. Peripheral Progenitor Cell Transplantation

  • 10.   Colony Stimulating Factors Market, By Dosage Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Injection
        2. Tablets
        3. Capsule
        4. Others

  • 11.   Colony Stimulating Factors Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Intravenous
        2. Subcutaneous
        3. Oral
        4. Others

  • 12.   Colony Stimulating Factors Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 13.   Colony Stimulating Factors Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 14.   North America Colony Stimulating Factors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 15.   Latin America Colony Stimulating Factors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 16.   Europe Colony Stimulating Factors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 17.   Asia Pacific Colony Stimulating Factors Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 18.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 19.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 20.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Intas Pharmaceuticals Ltd.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Sanofi
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Teva Pharmaceutical Industries Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. GlaxoSmithKline plc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Biocon
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Dr. Reddy’s Laboratories Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Amgen Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Merck KGaA
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
         11. Takeda Pharmaceutical Company Limited
          11.1. Company Overview
          11.2. Product Portfolio
          11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview
         12. Thermo Fisher Scientific Inc.
          12.1. Company Overview
          12.2. Product Portfolio
          12.3. SWOT Analysis
          12.4. Financial Overview
          12.5. Strategic Overview
         13. Stada Arzneimittel AG
          13.1. Company Overview
          13.2. Product Portfolio
          13.3. SWOT Analysis
          13.4. Financial Overview
          13.5. Strategic Overview
        14. Emcure Pharmaceuticals Limited.
          14.1. Company Overview
          14.2. Product Portfolio
          14.3. SWOT Analysis
          14.4. Financial Overview
          14.5. Strategic Overview
         15. Celltrion, Inc
          15.1. Company Overview
          15.2. Product Portfolio
          15.3. SWOT Analysis
          15.4. Financial Overview
          15.5. Strategic Overview
         16. Biocad
          16.1. Company Overview
          16.2. Product Portfolio
          16.3. SWOT Analysis
          16.4. Financial Overview
          16.5. Strategic Overview
         17. Coherus BioSciences
          17.1. Company Overview
          17.2. Product Portfolio
          17.3. SWOT Analysis
          17.4. Financial Overview
          17.5. Strategic Overview
         18. Johnson & Johnson Private Limited
          18.1. Company Overview
          18.2. Product Portfolio
          18.3. SWOT Analysis
          18.4. Financial Overview
          18.5. Strategic Overview
         19. Eli Lilly and Company.
          19.1. Company Overview
          19.2. Product Portfolio
          19.3. SWOT Analysis
          19.4. Financial Overview
          19.5. Strategic Overview
          20. Abbott
          20.1. Company Overview
          20.2. Product Portfolio
          20.3. SWOT Analysis
          20.4. Financial Overview
          20.5. Strategic Overview

  • 21.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 22.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients